Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
20
pubmed:dateCreated
2006-5-11
pubmed:abstractText
In order to identify novel candidates associated with prostate cancer metastasis, we compared the proteomic profile of the poorly metastatic human prostate cancer cell line LNCaP, with its highly metastatic variant LNCaP-LN3, by two-dimensional gel electrophoresis. A major protein spot (pI of 5.9 and molecular weight of 37 kDa) was seen in LNCaP cells, but not in LNCaP-LN3 cells and was identified as lactate dehydrogenase-B (LDHB), by tandem mass spectrometry. Furthermore, enzyme kinetic assays and zymography showed a higher LDH enzyme activity in LNCaP cells compared with LNCaP-LN3. Bisulphite-modified DNA sequencing showed promoter hypermethylation in LNCaP-LN3 cells but not in LNCaP, Du145, PC3, CWR22 or BPH45 cells. Treatment of LNCaP-LN3 cells with 5'-azacytidine caused re-expression of LDHB transcripts. In tissues, LDHB promoter hypermethylation occurred at a higher frequency in prostate cancer, 14/ 31 (45%), compared to adjacent nonmalignant or benign tissue, 2/19 (11%) (P < 0.025). Immunohistochemistry showed a higher frequency of LDHB expression in benign or non-malignant tissues, 59/ 73 (81%), compared to cancer cases, 3/53 (6%) (P < 0.001). Absent LDHB expression was also seen in 7/7 (100%) cases of metastatic cancer in bone. Our data are the first to show loss of LDHB expression in prostate cancer, the mechanism of which appears to involve promoter hypermethylation.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0950-9232
pubmed:author
pubmed:issnType
Print
pubmed:day
11
pubmed:volume
25
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2953-60
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:16547507-Amino Acid Sequence, pubmed-meshheading:16547507-Azacitidine, pubmed-meshheading:16547507-Base Sequence, pubmed-meshheading:16547507-Bone Neoplasms, pubmed-meshheading:16547507-DNA, Neoplasm, pubmed-meshheading:16547507-DNA Methylation, pubmed-meshheading:16547507-DNA Modification Methylases, pubmed-meshheading:16547507-Electrophoresis, Gel, Two-Dimensional, pubmed-meshheading:16547507-Enzyme Inhibitors, pubmed-meshheading:16547507-Gene Expression Regulation, Neoplastic, pubmed-meshheading:16547507-Gene Silencing, pubmed-meshheading:16547507-Humans, pubmed-meshheading:16547507-Isoenzymes, pubmed-meshheading:16547507-L-Lactate Dehydrogenase, pubmed-meshheading:16547507-Male, pubmed-meshheading:16547507-Molecular Sequence Data, pubmed-meshheading:16547507-Promoter Regions, Genetic, pubmed-meshheading:16547507-Prostatic Neoplasms, pubmed-meshheading:16547507-Proteomics, pubmed-meshheading:16547507-Tumor Cells, Cultured
pubmed:year
2006
pubmed:articleTitle
Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer.
pubmed:affiliation
Academic Urology Unit, Division of Clinical Sciences South, University of Sheffield, UK.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't